A cross-sectional study describing the characteristics of patients with crohn's disease across inflammatory, penetrating and/or stricturing phenotypes enrolled in the Study of a Prospective Adult Research Cohort with IBD (SPARC-IBD) from the IBD-Plexus®, a US-based multicenter registry program
Latest Information Update: 06 Jul 2021
At a glance
- Drugs Adalimumab (Primary) ; Infliximab (Primary) ; Ustekinumab (Primary) ; Vedolizumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms SPARC-IBD
- 06 Jul 2021 New trial record
- 23 May 2021 Results presented at the Digestive Disease Week 2021